New Research Highlights Antifungal Potential of Weissella cibaria Oral Probiotics
Key Findings
A new peer-reviewed study published in the Korean Journal of Microbiology (2025, Vol. 61, No. 3) reports that two proprietary oral probiotic strains, Weissella cibaria CMU (OraCMU) and CMS1 (OraCMS1), demonstrate strong antifungal activity against Candida albicans—the primary pathogen responsible for oral candidiasis (commonly known as oral thrush).
-
Inhibition of fungal growth and biofilm formation
Both OraCMU and OraCMS1 significantly suppressed the growth of Candida species and reduced biofilm formation by more than 90%. Biofilms are known to protect fungi from antifungal drugs, making them a major challenge in treatment. - Suppression of hyphal transition
The probiotics also blocked the transformation of C. albicans from its benign yeast form into the invasive filamentous form (hyphae), a critical step in disease progression. - Downregulation of virulence genes
Treatment with probiotic supernatants led to reduced expression of key genes (BCR1, EFG1, UME6, NRG1) that drive biofilm development and fungal pathogenicity. - Synergy with natural extracts
When combined with black raspberry extract, OraCMU’s antifungal activity was enhanced, suggesting potential for innovative “synbiotic” formulations. - Superior to commercial probiotics
In direct comparisons, OraCMU and OraCMS1 outperformed several well-known commercial oral probiotic strains in inhibiting Candida.
Why This Matters
A new peer-reviewed study published in the Korean Journal of Microbiology (2025, Vol. 61, No. 3) reports that two proprietary oral probiotic strains, Weissella cibaria CMU (OraCMU) and CMS1 (OraCMS1), demonstrate strong antifungal activity against Candida albicans—the primary pathogen responsible for oral candidiasis (commonly known as oral thrush).
Ready to unleash the power of probiotics?
Revolutionize your oral care routine with Oraticx probiotics!
